These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37147105)

  • 1. Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
    Thomas MG; Dermawan A; Teh S
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37147105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
    Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
    BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
    Hassan YAM; Daud Ali M; Al-Eid RR; Al-Ghuraya FA; Essa Alqasimi Z; Ahmad A; Eltrafi Z; Ghosn SA
    Vaccine; 2022 Nov; 40(49):7087-7096. PubMed ID: 36404426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine.
    Luo A; Oakley A
    Australas J Dermatol; 2022 Aug; 63(3):e247-e250. PubMed ID: 35607272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical Presentation of Erythema Nodosum Following Pfizer-BioNTech COVID-19 Vaccine.
    Alzoabi N; Alqahtani J; Algamdi B; Almutairi M; Alratroot J; Alkhaldi S; Alqahtani S; Alakloby O
    Med Arch; 2022 Feb; 76(1):72-74. PubMed ID: 35422564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
    Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
    Vaccine; 2023 Jan; 41(2):460-466. PubMed ID: 36481108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
    Yasmin F; Najeeb H; Naeem U; Moeed A; Atif AR; Asghar MS; Nimri N; Saleem M; Bandyopadhyay D; Krittanawong C; Fadelallah Eljack MM; Tahir MJ; Waqar F
    Immun Inflamm Dis; 2023 Mar; 11(3):e807. PubMed ID: 36988252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes Zoster Following COVID-19 Vaccine Booster.
    Shahrudin MS; Mohamed-Yassin MS; Nik Mohd Nasir NM
    Am J Case Rep; 2023 Jan; 24():e938667. PubMed ID: 36650730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood primary angiitis of the central nervous system following COVID-19 vaccination (BNT162b2/Pfizer-BioNtech): A case report.
    Ariyoshi T; Hoshide M; Motonaga T; Korenaga Y; Azuma Y; Ichimura T; Matsushige T; Hasegawa S
    Hum Vaccin Immunother; 2023 Aug; 19(2):2261167. PubMed ID: 37772503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbations of Idiopathic Systemic Capillary Leak Syndrome following BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech).
    Akiyama Y; Inagaki T; Morioka S; Kusano E; Ohmagari N
    Intern Med; 2023 Jul; 62(13):2013-2017. PubMed ID: 37081683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.
    Nachtigall I; Bonsignore M; Hohenstein S; Bollmann A; Günther R; Kodde C; Englisch M; Ahmad-Nejad P; Schröder A; Glenz C; Kuhlen R; Thürmann P; Meier-Hellmann A
    BMC Infect Dis; 2022 Mar; 22(1):291. PubMed ID: 35346089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
    Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.